Pay-For-Delay, REMS Reform Legislation Making (Slow) Progress In House

It does not appear that Congress is ready to take up any new legislative proposals related to antitrust issues in the US FDA approval process in the near future, as members likely need more time to educate themselves on the issue.

Members of House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law spent much of a July 27 hearing asking witnesses – which included FDA Commissioner Scott Gottlieb, Federal Trade Commission (FTC) Acting Director of the Bureau of Competition Markus Meier and a panel of policy experts